These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 15472342)
21. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. Li MW; Hou W; Wo JE; Liu KZ J Zhejiang Univ Sci B; 2005 Jul; 6(7):664-7. PubMed ID: 15973769 [TBL] [Abstract][Full Text] [Related]
22. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes. Selabe SG; Song E; Burnett RJ; Mphahlele MJ J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250 [TBL] [Abstract][Full Text] [Related]
23. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains. Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378 [TBL] [Abstract][Full Text] [Related]
24. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine. Yang DH; Liang WF; Xie YJ; Zhao NF; Fan J Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274 [TBL] [Abstract][Full Text] [Related]
25. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501 [TBL] [Abstract][Full Text] [Related]
26. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Yeh CT; Chien RN; Chu CM; Liaw YF Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158 [TBL] [Abstract][Full Text] [Related]
27. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063 [TBL] [Abstract][Full Text] [Related]
28. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients. Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742 [TBL] [Abstract][Full Text] [Related]
29. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Tipples GA; Ma MM; Fischer KP; Bain VG; Kneteman NM; Tyrrell DL Hepatology; 1996 Sep; 24(3):714-7. PubMed ID: 8781348 [TBL] [Abstract][Full Text] [Related]
30. Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR. Peng XM; Gu L; Huang YS; Ma HH; Xie QF; Li G; Gao ZL J Virol Methods; 2005 Sep; 128(1-2):168-75. PubMed ID: 15950294 [TBL] [Abstract][Full Text] [Related]
31. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116 [TBL] [Abstract][Full Text] [Related]
32. Dynamics of hepatitis B virus resistance to lamivudine. Pallier C; Castéra L; Soulier A; Hézode C; Nordmann P; Dhumeaux D; Pawlotsky JM J Virol; 2006 Jan; 80(2):643-53. PubMed ID: 16378967 [TBL] [Abstract][Full Text] [Related]
33. Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case. Bottecchia M; Ikuta N; Niel C; Araujo NM; O KM; Gomes SA J Gastroenterol Hepatol; 2008 Jan; 23(1):67-72. PubMed ID: 18171343 [TBL] [Abstract][Full Text] [Related]
34. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment]. Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947 [TBL] [Abstract][Full Text] [Related]
35. Dual-probe assay for detection of lamivudine-resistance hepatitis B virus by real-time PCR. Geng H; Hua B; Wang H; Cao Y; Sun Y; Yu A J Virol Methods; 2006 Mar; 132(1-2):25-31. PubMed ID: 16198006 [TBL] [Abstract][Full Text] [Related]
36. Quantification of lamivudine-resistant hepatitis B virus mutants by type-specific TaqMan minor groove binder probe assay in patients with chronic hepatitis B. Yoshida S; Hige S; Yoshida M; Yamashita N; Fujisawa S; Sato K; Kitamura T; Nishimura M; Chuma M; Asaka M; Chiba H Ann Clin Biochem; 2008 Jan; 45(Pt 1):59-64. PubMed ID: 18275675 [TBL] [Abstract][Full Text] [Related]
37. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids. Mori K; Minami M; Kirishima T; Kunimoto K; Okita M; Nakayama M; Makiyama A; Yamaoka J; Nakajima T; Yasui K; Itoh Y; Okanoue T Intervirology; 2006; 49(5):274-80. PubMed ID: 16714856 [TBL] [Abstract][Full Text] [Related]
38. Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus. Jang H; Cho M; Heo J; Kim H; Jun H; Shin W; Cho B; Park H; Kim C J Clin Microbiol; 2004 Sep; 42(9):4181-8. PubMed ID: 15365009 [TBL] [Abstract][Full Text] [Related]
39. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. Lee CZ; Lee HS; Huang GT; Yang PM; Sheu JC World J Gastroenterol; 2006 Sep; 12(33):5301-5. PubMed ID: 16981258 [TBL] [Abstract][Full Text] [Related]
40. [Detection of lamivudine-resistant hepatitis B virus]. Matsumura M Nihon Rinsho; 2004 Aug; 62 Suppl 8():175-9. PubMed ID: 15453310 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]